These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20814015)

  • 1. Cholesterol intake modulates plasma triglyceride levels in glycosylphosphatidylinositol HDL-binding protein 1-deficient mice.
    Weinstein MM; Tu Y; Beigneux AP; Davies BS; Gin P; Voss C; Walzem RL; Reue K; Tontonoz P; Bensadoun A; Fong LG; Young SG
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2106-13. PubMed ID: 20814015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
    Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired thermogenesis and sharp increases in plasma triglyceride levels in GPIHBP1-deficient mice during cold exposure.
    Larsson M; Allan CM; Heizer PJ; Tu Y; Sandoval NP; Jung RS; Walzem RL; Beigneux AP; Young SG; Fong LG
    J Lipid Res; 2018 Apr; 59(4):706-713. PubMed ID: 29449313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice.
    Davis HR; Compton DS; Hoos L; Tetzloff G
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2032-8. PubMed ID: 11742881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GPIHBP1-independent pathway for clearance of plasma TGs in
    Cushing EM; Sylvers KL; Chi X; Shetty SK; Davies BSJ
    J Lipid Res; 2018 Jul; 59(7):1230-1243. PubMed ID: 29739862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
    van Heek M; Austin TM; Farley C; Cook JA; Tetzloff GG; Davis HR
    Diabetes; 2001 Jun; 50(6):1330-5. PubMed ID: 11375333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum levels of angiopoietin-like protein-8 and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 after ezetimibe therapy in patients with dyslipidemia.
    Ideishi A; Suematsu Y; Tashiro K; Morita H; Kumagai-Koyanagi N; Kuwano T; Miura SI
    Clin Chim Acta; 2020 Nov; 510():675-680. PubMed ID: 32858055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys.
    van Heek M; Compton DS; Davis HR
    Eur J Pharmacol; 2001 Mar; 415(1):79-84. PubMed ID: 11245855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimibe ameliorates cholecystosteatosis.
    Mathur A; Walker JJ; Al-Azzawi HH; Lu D; Swartz-Basile DA; Nakeeb A; Pitt HA
    Surgery; 2007 Aug; 142(2):228-33. PubMed ID: 17689690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A lipoprotein lipase-GPI-anchored high-density lipoprotein-binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome.
    Nimonkar AV; Weldon S; Godbout K; Panza D; Hanrahan S; Cubbon R; Xu F; Trauger JW; Gao J; Voznesensky A
    J Biol Chem; 2020 Mar; 295(10):2900-2912. PubMed ID: 31645434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
    Sandoval JC; Nakagawa-Toyama Y; Masuda D; Tochino Y; Nakaoka H; Kawase R; Yuasa-Kawase M; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Ohama T; Matsuyama A; Nishida M; Ishigami M; Komuro I; Yamashita S
    J Atheroscler Thromb; 2010 Sep; 17(9):914-24. PubMed ID: 20543519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between skeletal muscle mass and serum concentrations of lipoprotein lipase, GPIHBP1, and hepatic triglyceride lipase in young Japanese men.
    Matsumoto R; Tsunekawa K; Shoho Y; Yanagawa Y; Kotajima N; Matsumoto S; Araki O; Kimura T; Nakajima K; Murakami M
    Lipids Health Dis; 2019 Apr; 18(1):84. PubMed ID: 30947712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An upstream enhancer regulates
    Allan CM; Heizer PJ; Tu Y; Sandoval NP; Jung RS; Morales JE; Sajti E; Troutman TD; Saunders TL; Cusanovich DA; Beigneux AP; Romanoski CE; Fong LG; Young SG
    J Lipid Res; 2019 Apr; 60(4):869-879. PubMed ID: 30598475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.
    Braun A; Yesilaltay A; Acton S; Broschat KO; Krul ES; Napawan N; Stagliano N; Krieger M
    Atherosclerosis; 2008 May; 198(1):77-84. PubMed ID: 18054357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.
    Altmann SW; Davis HR; Yao X; Laverty M; Compton DS; Zhu LJ; Crona JH; Caplen MA; Hoos LM; Tetzloff G; Priestley T; Burnett DA; Strader CD; Graziano MP
    Biochim Biophys Acta; 2002 Jan; 1580(1):77-93. PubMed ID: 11923102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular protective effects of ezetimibe in ApoE-deficient mice.
    Nakagami H; Osako MK; Takami Y; Hanayama R; Koriyama H; Mori M; Hayashi H; Shimizu H; Morishita R
    Atherosclerosis; 2009 Mar; 203(1):51-8. PubMed ID: 18603252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
    Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
    Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
    Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
    J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.
    van Heek M; Farley C; Compton DS; Hoos L; Davis HR
    Br J Pharmacol; 2001 Sep; 134(2):409-17. PubMed ID: 11564660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.